Skip to main content
SpringerLink
Log in

Cardiac Toxic Chemotherapy and Cancer Survivorship

  • Chapter
  • First Online:
Cardio-Oncology

  • 886 Accesses

Abstract

With remarkable progress in cancer diagnosis and therapy, there are growing numbers of cancer survivors with almost 15 million current survivors in the United States. Because of the recognition that cardiovascular morbidity and mortality play an important role in outcomes of cancer survivors, understanding the unique cardiac needs of survivors and existing evidence for care is essential to cardio-oncology and survivorship care. Cancer survivors are a heterogeneous population with several potentially cardiotoxic exposures and several potential, and not mutually exclusive, complications of therapy (for instance cardiomyopathy and premature atherosclerosis) making uniform guidelines difficult to implement. Using case-based presentations, this chapter will address basic assessment and management of cardiac function and risk in cancer survivors. Best practices for assessment of survivors based on treatment modality (i.e., chemotherapy and/or radiation therapy) and host-related factors (i.e., age at diagnosis and pre-existing risk factors) are described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Parry C, Kent EE, Mariotto AB, et al. Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev. 2011;20:1996–2005.

    Article  PubMed  PubMed Central  Google Scholar 

  2. American Cancer Society. Cancer treatment and survivorship facts & figures 2014–2015. Atlanta: American Cancer Society; 2014.

    Google Scholar 

  3. Smith MA, Altekruse SF, Adamson PC, et al. Declining childhood and adolescent cancer mortality. Cancer. 2014;120:2497–506.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Eng J Med. 2006;355:1572–82.

    Article  CAS  Google Scholar 

  5. Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe life threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol. 2014;32:1218–27.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lipshultz SE, Adams J, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention and research directions. A scientific statement from the American Heart Association. Circulation. 2013;128:1927–95.

    Article  PubMed  Google Scholar 

  7. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;1:1–10.

    Article  Google Scholar 

  8. Bovelli D, Plataniokis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease. ESMO clinical practice guidelines. Ann Oncol. 2010;21 Suppl 5:277–82.

    Article  Google Scholar 

  9. Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;111:412–8.

    Article  Google Scholar 

  10. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011;154:23–31.

    Article  PubMed  Google Scholar 

  12. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36.

    Article  CAS  PubMed  Google Scholar 

  13. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991–8.

    Article  CAS  PubMed  Google Scholar 

  14. Carver JR, Shapiro CL, Ng A, et al. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the emerging care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4009.

    Article  CAS  PubMed  Google Scholar 

  15. Steingart RM, Yadav N, Manrique C, et al. Cancer survivorship: Cardiotoxic therapy in the adult cancer patient; Cardiac outcomes with recommendations for patient management. Semin Oncol. 2013;40:690–708.

    Article  PubMed  Google Scholar 

  16. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466–73.

    Article  CAS  PubMed  Google Scholar 

  17. Armenian SH, Ding Y, Mills G, et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol. 2013;163:205–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Lipshultz SE, Lipsitz SR, Kutok JL, et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013;119:3555–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genetics. 2015;47:1079–84.

    Article  CAS  PubMed  Google Scholar 

  20. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACC/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Col Cardiol. 2009;53:1343–82.

    Article  Google Scholar 

  21. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977–82.

    Article  PubMed  Google Scholar 

  22. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Eng J Med. 1992;327:685–91.

    Article  Google Scholar 

  23. Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplan. 2004;23:1313–33.

    Article  Google Scholar 

  24. Amigioni M, Giannattosio C, Frashini D, et al. Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors. Ped Blood Cancer. 2010;55:1343–7.

    Article  Google Scholar 

  25. Vandecruys E, Mondelaers V, De Wolf D, et al. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Surviv. 2012;6:95–101.

    Article  PubMed  Google Scholar 

  26. Smith LA, Cpornelius VR, Plummer CS, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systemic review and meta-analysis of randomized cancer trials. BMC Cancer. 2010;10:337.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with an end in mind. J Clin Oncol. 2010;28:1276–80.

    Article  PubMed  Google Scholar 

  28. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 2010;53:121–9.

    Article  CAS  PubMed  Google Scholar 

  29. Ky B, Carver JR. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy. Heart Fail Clin. 2011;7:323–31.

    Article  PubMed  Google Scholar 

  30. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic proteins in acute cardiac care; a position statement from the Study Group on biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33:2001–16.

    Article  CAS  PubMed  Google Scholar 

  31. Putt M, Hahn VS, Januzzi JL, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes and trastuzumab. Clin Chem. 2015;61:1164–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Plano JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–39.

    Article  Google Scholar 

  33. Greenland P, Alpert JS, Beller GA, et al. The 2010 Joint American College of Cardiology Foundation/American Heart Association guidelines for the assessment of cardiovascular risk in asymptomatic adults. J Am Coll Cardiol. 2010;56:50–103.

    Article  Google Scholar 

  34. U.S. Preventive Services Task Force. Screening for coronary artery disease: recommendation statement. Ann Int Med. 2004;140:569–72.

    Article  Google Scholar 

  35. U.S. Preventive Services Task Force. Using non-traditional risk factors in coronary heart disease risk assessment: recommendation statement. Ann Int Med. 2009;151:474–82.

    Article  Google Scholar 

  36. Hewitt M, Weiner SL, Simone JV. Childhood cancer survivorship: Improving care and quality of life. Washington, DC: National Academics Press; 2003.

    Google Scholar 

  37. Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: Lost in transition. Washington, DC: National Academics Press; 2006.

    Google Scholar 

  38. Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood and adolescent and young adult cancer. Vesion 4.0, 2014. www.survivorshipguidelines.org.

  39. Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16:e123–36.

    Article  PubMed  PubMed Central  Google Scholar 

  40. deHaas EC, Oosting SF, Lefrandt JD, et al. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010;11:193–203.

    Article  CAS  Google Scholar 

  41. Bowers DC, Liu Y, Leisenting W, et al. Late-occurring stroke among long-term survivors of chronic leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:5277–80.

    Article  PubMed  Google Scholar 

  42. Edgar AB, Wallace HB. Pregnancy in women who had childhood cancer. Eur J Cancer. 2007;43:1890–4.

    Article  PubMed  Google Scholar 

  43. Baker KS, Armenian S, Bhatia S. Long-term consequences of hematopoietic stem-cell transplantation: current state of the science. Bio Blood Marrow Transplant. 2010;1(Suppl):S90–6.

    Article  Google Scholar 

  44. Dorresteijn LD, Marres HA, Bartelink H, et al. Radiotherapy of the neck as a risk factor for stroke. Ned Tijdschr Geneeskd. 2005;149:1249–53.

    CAS  PubMed  Google Scholar 

  45. Plummer C, Henderson RD, O’Sullivan SJ. Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. Stroke. 2011;42:2410–8.

    Article  PubMed  Google Scholar 

  46. Seddon B, Cook A, Gothard L, et al. Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol. 2002;64:53–63.

    Article  PubMed  Google Scholar 

  47. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol. 2007;25:43–9.

    Article  PubMed  Google Scholar 

  49. Kupeli S, Hazirolan T, Varnan A, et al. Evaluation of coronary artery disease by computed tomography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol. 2010;28:1025–30.

    Article  PubMed  Google Scholar 

  50. Armstrong GT, Oeffinger KC, Chen C, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31:3673–80.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Armenian SH, Sun CL, Vase T, et al. Cardiovascular risk factors in hematopoietic stem cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood. 2012;120:4505–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Patnaik JL, Byers T, DiGuiseppi C, et al. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011;103:1101–11.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99:365–75.

    Article  PubMed  Google Scholar 

  54. Bruning PF, Bonfrer JM, Hart AA, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988;58:487–99.

    Article  Google Scholar 

  55. Pritchard KI, Abramson BL. Cardiovascular health and aromatase inhibitors. Drugs. 2006;66:1727–40.

    Article  CAS  PubMed  Google Scholar 

  56. Albini A, Pennesi G, Donatelli I, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kalogereropoulis A, Psaty BM, Vasan RS, et al. Validation of the Health ABC Heart Failure model for incident heart failure risk prediction: the Cardiovascular Health Study. Circ Heart Fail. 2010;3:495–502.

    Google Scholar 

  58. Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol. 2011;22:1011–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abramson Cancer Center, Cancer Survivorship Program, Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Dava Szalda

  2. Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Monica Ahluwalia

  3. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Joseph R. Carver

Authors
  1. Dava Szalda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Ahluwalia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph R. Carver
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph R. Carver .

Editor information

Editors and Affiliations

  1. Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA

    Gretchen G. Kimmick

  2. Vanderbilt Heart and Vascular Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Daniel J. Lenihan

  3. Maine Medical Center, Cardiovascular Institute, Portland, Maine, USA

    Douglas B. Sawyer

  4. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

    Erica L. Mayer

  5. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA

    Dawn L. Hershman

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

(PPTX 452 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Szalda, D., Ahluwalia, M., Carver, J.R. (2017). Cardiac Toxic Chemotherapy and Cancer Survivorship. In: Kimmick, G., Lenihan, D., Sawyer, D., Mayer, E., Hershman, D. (eds) Cardio-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-43096-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43096-6_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43094-2

  • Online ISBN: 978-3-319-43096-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation